Agilent Awards Trilogy Sciences a Golden Ticket at LabCentral

Agilent Technologies has awarded biotech startup Trilogy Sciences a "Golden Ticket," providing one year of funded lab bench space at LabCentral, a biotech innovation hub in Cambridge, Massachusetts.

The award, announced after a virtual event on May 5, 2020, aims to support Trilogy Sciences' mission to develop therapeutics for untreatable diseases. The company utilizes advanced chemical biology to rapidly synthesize and screen for hyper-effective drugs targeting recurrent breast, brain, and lung cancers.

Agilent, a platinum sponsor of LabCentral, equipped the shared lab space with instrumentation including a mass spectrometry system and a cell analysis analyzer. The "Golden Ticket" program allows early-stage companies access to LabCentral's collaborative environment and Agilent's resources.

Agilent Technologies operates in the life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and solutions to customers worldwide.